Trial Profile
A Phase I, Open-label, Dose-finding Study to Assess the Safety, Tolerability and Pharmacokinetics of ISU104, a Human Monoclonal Antibody Targeting ErbB3 in Patients With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 May 2023
Price :
$35
*
At a glance
- Drugs Barecetamab (Primary) ; Cetuximab (Primary)
- Indications Advanced breast cancer; Head and neck cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors ISU Abxis
- 03 May 2021 Planned End Date changed from 14 Dec 2020 to 31 Dec 2021.
- 03 May 2021 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2020 Results (As of 17th Jul 2020, n=18) of dose-expansion (PART II) assessing safety and toleratibility of ISU104 alone and combination with cetuximab, presented at the 45th European Society for Medical Oncology Congress